Considering the high mortality of untreated GATA2 deficiency and the high likelihood of developing MDS/AML, these data support a strategy of early preemptive HSCT in all pediatric patients with GATA2 deficiency. This evidence concerns the gene GATA2 and myelodysplastic syndrome.